Ardea Biosciences (RDEA), which closed the day with a market cap of $470.4M, has filed for a $150M mixed shelf offering. The company plans to partly use the proceeds to help fund a clinical trial for its Lesinurad drug for treating gout.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs